Arvinas Q2 2026 earnings: Licensing revenue drives a return to profit
TradingKey·- Arvinas reported Q2 2026 revenue of $249.7 million and a net income of $169.4 million, successfully swinging to a profit driven by Pfizer collaboration revenue, the Rigel license agreement, and a $50.0 million FDA approval milestone for VEPPANU. - Total operating expenses declined by $8.3 million to $85.6 million, primarily due to lower R&D spending, while cash, cash equivalents, and marketable securities totaled $567.9 million at June 30, 2026. - The company's cash resources are projected to fund operations into the second half of 2028, with future performance depending on Rigel's execution, upcoming early-stage pipeline data, and ongoing cash management.Rigel Pharmaceuticals posts corporate deck highlighting VEPPANU in-license and commercial launch plan
PUBT·- Rigel Pharmaceuticals highlighted its exclusive global license for VEPPANU in metastatic breast cancer, with a commercial launch planned for mid-August 2026. - The company projected 2026 net product sales of USD 260 million and reported Q2 2026 portfolio sales of USD 47.4 million, reflecting a 14% year-over-year increase. - Rigel closed 2025 with a cash balance of USD 155 million to support commercial expansion, pipeline advancement, and strategic in-licensing.RIGL: Rigel licensed VEPPANU from Arvinas/Pfizer for $70M upfront plus milestones and royalties
Quartr·- Rigel Pharmaceuticals secured an exclusive global license for VEPPANU from Arvinas and Pfizer for $70 M upfront alongside milestones and royalties. - The transaction was financed by amending Rigel's credit facility and grants the company full commercial rights and responsibilities. - The agreement positions VEPPANU for a commercial launch in August 2026.